ARDX (Ardelyx Pharma) Future Price to Earnings

Brandmark of ardelyx.com (ARDX)

Stable production of approved drugs in the US ensures the resilience of Ardelyx, Inc. (ARDX). The company's valuation based on forward P/E confirms this trend, with the metric standing at 16.30. Growth prospects are based on R&D in ion exchange and the expansion of hyperphosphatemia treatments, creating a powerful patent moat for long-term business development.

ARDX - ardelyx.com Market Cap to Projected Earnings over the range 07/04/2022 - 11/14/2026

Ardelyx Corp (ARDX) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Quotes Ardelyx|ARDX - Fair Value Consensus
- business market valuation indicators:
Market Value Ardelyx Inc|ARDX - Enterprise Value
- balance sheet equity data:
Book Value per Share Ardelyx|ARDX - Book Valuation of Business|Market Capitalization to Book Value Ratio ardelyx.com|ARDX - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity Ardelyx, Inc.|ARDX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Ardelyx, Inc.|ARDX - Company Cumulative Debt|Debt to Book Value Ardelyx Inc|ARDX - Long-Term Debt|Company Short-Term Debts Ardelyx|Quick Liquidity ardelyx.com
- earnings and market ratios statistics:
ARDX - Final Profit|Projected Future Earnings Ardelyx, Inc.|ARDX - Price to Earnings Multiple|Forward P/E Multiple Ardelyx Pharma|ARDX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ardelyx Inc|ARDX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Ardelyx|ARDX - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months ardelyx.com|ARDX - Earnings per share growth this year|Expected earnings per share growth for next year Ardelyx, Inc.
- revenue and sales proceeds data:
ARDX - Company Sales Revenue|Projected Sales Volume Ardelyx|ARDX - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Ardelyx Inc
Analysis of all company metrics:Ardelyx ARDX
Signature product of Ardelyx Corp

Forward P/E determines the stock value relative to projected earnings for a future period. The ratio is calculated by dividing the current price by the expected annual net income. By analyzing the forward P/E for the coming year, an investor assesses the degree of optimism priced in. For Ardelyx, Inc. (ARDX), this metric is sensitive to Medicare reimbursement rates. Risks of secondary offerings and slow drug adoption could significantly adjust the final value of the multiple.

Competitors of Ardelyx, Inc. (ARDX)

Projected Price to Earnings TVTX (Travere Therapeutics, Inc.)|PROK (ProKidney Corp) - Future Price to Earnings Multiple|Future Price to Earnings Akebia AKBA|Forward P/E Multiple Cara Corp TVRD|DiaMedica Therapeutics - Forward P/E Multiple|Market Cap to Projected Earnings unicycive.com UNCY|RMTI: Forward P/E Multiple|Price to Future Earnings Ratio CVKD|Future Price to Earnings Conduit Pharma|Price to Future Earnings Ratio CALT (Calliditas)|Forward P/E Multiple RNLX|ZVSA - Projected Price to Earnings Ratio